Erasca says 44% of 25 responded; it’s Phase 1
About 37 min read
Every edition you can open, newest first. Each brief's latest edition is free to read; subscribers to a brief get its back issues too.
About 37 min read
44 earlier editions for Biotech & Pharma subscribers · Biotech & Pharma home
About 32 min read
44 earlier editions for AI & Technology subscribers · AI & Technology home
9 earlier editions for Worldview subscribers · Worldview home
About 31 min read
1 earlier edition for Life subscribers · Life home